Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Mar 12, 2024 (filed on Mar 13, 2024)Insider Name:Brown Scott B.Ownership Type:Direct OwnershipSecurities:Employee Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:224,800Price:--
-
Mar 12, 2024 (filed on Mar 13, 2024)Insider Name:Theuer CharlesOwnership Type:Direct OwnershipSecurities:Employee Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:518,300Price:--
-
Oct 20, 2023 (filed on Mar 13, 2024)Insider Name:Theuer CharlesOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:3,500Price:$0.13
-
Apr 27, 2023 (filed on Apr 28, 2023)Insider Name:Theuer CharlesOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:47,000Price:$0.75
-
Apr 26, 2023 (filed on Apr 28, 2023)Insider Name:Theuer CharlesOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:3,999Price:$0.66
-
Apr 20, 2023 (filed on Mar 13, 2024)Insider Name:Brown Scott B.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:3,500Price:$0.14
-
Apr 20, 2023 (filed on Mar 13, 2024)Insider Name:Theuer CharlesOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:3,500Price:$0.14
-
Apr 19, 2023 (filed on Apr 21, 2023)Insider Name:Johnson-Pratt LisaOwnership Type:Direct OwnershipSecurities:Director Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:18,000Price:--
-
Apr 19, 2023 (filed on Apr 21, 2023)Insider Name:Lam Carol C.Ownership Type:Direct OwnershipSecurities:Director Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:18,000Price:--
-
Apr 19, 2023 (filed on Apr 21, 2023)Insider Name:Pelletier Saundra LOwnership Type:Direct OwnershipSecurities:Director Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:18,000Price:--
Filings by filing date
-
Mar 12, 2024 (filed on Mar 13, 2024)Insider Name:Brown Scott B.Ownership Type:Direct OwnershipSecurities:Employee Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:224,800Price:--
-
Apr 20, 2023 (filed on Mar 13, 2024)Insider Name:Brown Scott B.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:3,500Price:$0.14
-
Mar 12, 2024 (filed on Mar 13, 2024)Insider Name:Theuer CharlesOwnership Type:Direct OwnershipSecurities:Employee Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:518,300Price:--
-
Oct 20, 2023 (filed on Mar 13, 2024)Insider Name:Theuer CharlesOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:3,500Price:$0.13
-
Apr 20, 2023 (filed on Mar 13, 2024)Insider Name:Theuer CharlesOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:3,500Price:$0.14
-
Apr 27, 2023 (filed on Apr 28, 2023)Insider Name:Theuer CharlesOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:47,000Price:$0.75
-
Apr 26, 2023 (filed on Apr 28, 2023)Insider Name:Theuer CharlesOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:3,999Price:$0.66
-
Apr 19, 2023 (filed on Apr 21, 2023)Insider Name:Johnson-Pratt LisaOwnership Type:Direct OwnershipSecurities:Director Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:18,000Price:--
-
Apr 19, 2023 (filed on Apr 21, 2023)Insider Name:Lam Carol C.Ownership Type:Direct OwnershipSecurities:Director Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:18,000Price:--
-
Apr 19, 2023 (filed on Apr 21, 2023)Insider Name:Pelletier Saundra LOwnership Type:Direct OwnershipSecurities:Director Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:18,000Price:--
News
Biz Brief
Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 4350 LA JOLLA VILLAGE DRIVE, SUITE 800 SAN DIEGO CA 92122 |
Tel: | N/A |
Website: | https://www.traconpharma.com |
IR: | See website |
Key People | ||
Charles P. Theuer Chairman of the Board, President, Chief Executive Officer | Scott B. Brown Chief Financial Officer |
Business Overview |
TRACON Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing its contract research organization (CRO) independent product development platform to partner with other life science companies to develop and commercialize products in the United States. The Company's clinical-stage oncology product candidate is TRC102, which is a small molecule that has been studied in Phase 1 and Phase 2 trials for the treatment of mesothelioma, lung cancer, glioblastoma and solid tumors and YH001, which is a monospecific investigational cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody. TRC102 is a small molecule in clinical development to reverse resistance to specific chemotherapeutics by inhibiting DNA base excision repair (BER). Its clinical-stage product candidate, Envafolimab, is a PD-L1 antibody that is being developed for the treatment of sarcoma. |
Financial Overview |
For the fiscal year ended 31 December 2023, TRACON Pharmaceuticals Inc revenues increased from $0K to $12M. Net loss decreased 88% to $3.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Other income (expense), net increase from $247K (expense) to $13M (income), General and Administrative - other decrease of 56% to $5.6M (expense). |
Employees: | 17 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | N/A |
Annual revenue (TTM): | $12.05M as of Dec 31, 2023 |
EBITDA (TTM): | -$6.88M as of Dec 31, 2023 |
Net annual income (TTM): | -$3.59M as of Dec 31, 2023 |
Free cash flow (TTM): | $3.68M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 2,275,226 as of Apr 10, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |